chanisms network, while on the other -production of cytokines and cytokine mediated destruction of various organs and tissues [2, 19] . Therefore, increased levels of endotoxin against the developing neutropenia may suppress significantly the protective capacity of the immune system. However the clinical significance of endotoxinemia elevated indicators in case of AVT has not been detected yet, nor have its potential negative effects.
The purpose of the study is to investigate the serum levels of endotoxin against neutropenia in patients with CHC who undergo antiviral therapy, as well as detecting pharmacologic corrections for endotoxinemia.
Material and Methods. The course of neutropenia through AVT was investigated in 101 patients diagnosed with chronic hepatitis C -38 females and 63 males. The age varied from 18 to 62 (37.6±0.7 yrs). 62 of the patients (61.4 %) had HCV genotype 1 infection while others revealed non-1 (HCV genotypes 2 and 3). The average level of viremia was 4.9±1.2 log10. None of the patients was diagnosed with any hepatic cirrhosis stage.
In all the patients the combined AVT was administered with IFN-α and Ribavirin. Of them 83 patients were given PEG-IFN-α-2a (Pegasys), while another 18 -short-acting IFN-α. The duration of the therapy depended on the HCV genotype -24 weeks in case of HCV genotypes 2 and 3, and 48 weeks in case of HCV genotype 1.
The serum levels of endotoxin were detected with chromogenic assay (Hbt LAL Hycult Вiotech, Netherlands). The control group included 20 healthy volunteers aged 21-42 yrs.
The results obtained were processed using Microsoft Excel, Biostat, and STATISTICA 6.0. The comparative analysis of the parameters in groups with normal distribution was done using Student's t-test; for groups with non-normal distribution -Mann-Whitney test. Spearman's rank correlation coefficient was employed to reveal the correlation dependence.
Results and Discussion. The total number of leukocytes and the number of neutrophils prior to the antiviral therapy were within the normal ranges. There is data saying that patients with hepatitis C initially have a lower count of neutrophils if compared to the control group [5] . At the same time the level of neutrophils below 2900 cells/mcl at the start of the therapy was recommended as a predictor of severe neutropenia during treatment [11] .
In two weeks of AVT already the number of neutrophils went down reaching the minimum by Week 12, after which the level of neutropenia remained stable until Week 24. However, in patients with HCV genotype 1 the level of neutrophils on Week 48 was lower than on Week 24 (р=0.015). In the course of antiviral therapy, 62 patients developed grade 2 neutropenia (<1.5×10 9 /l) (54 patients who were treated with Pegasys, and 8 -with short-acting IFN-α). Neutrophil count reduction (grade 3 neutropenia)<1.0×10 9 /l through the course of AVT was more often observed in case of using pegylated drug (28.5 %), rather than when employing short-acting IFN-α (8 %; р=0.001). There was no dependence observed of neutropenia development on sex or age. At the same time literature contains evidence of direct relation between age and neutropenia developing through AVT, which was the case, in particular, with patients aged over 60 [13] .
Prior to AVT the patients with CHC had blood levels of endotoxin no different from those in healthy people. The endotoxin indices revealed no dependence on the patients' sex or age. Through the course of AVT against developing neutropenia, from Week 8 on, there was an increase in the blood endotoxin levels observed in all the patients (Table 1 ). Increased endotoxinemia remained there up until the end of the treatment. During that, in the cases with neutropenia (the number of cells <1.5×10 9 /l) the endotoxin levels were significantly higher than in patients with no neutropenia ( Table 2 ). The significance of this difference in groups demonstrating different levels of neutrophils showed up on Week 8 of AVT already and remained further. An increase in the endotoxinemia given the reduction in the absolute number of neutrophils is a perfect illustration of endotoxin-neutralizing capacity found in granulocytic cells. This dependence could be proven through an inverse relationship we detected between the endotoxin levels and the number of neutrophils (Rs= -0.74). There is no single shared opinion on the need to correct neutropenia in patients with CHC who undergo AVT. Oncological practice suggests that patients with neutropenia<500 cells/mcl who undergo polychemotherapy need antibiotics treatment. However, neutropenia developing against AVT in the range of 1000-1500 cells/mcl often remains not associated with bacterial complications and is not believed to need correction [6, 12, 17] . The existing standards in AVT state that in case of neutrophils going down< 750 cells/mcl the PEG-IFN dose should be reduced by 50 %, while in case the index above is< 500 cells/mcl the treatment has to be discontinued. At the same time, it is noted that in 10-20 % of cases neutropenia is the most common cause for reduction of the interferon dose and the frequency of sustained virologic response [6] .
An alternative to interferon dose reduction is granulocyte colony-stimulating factor (G-CSF) administration, in particular Filgrastim -a recombinant human G-CSF, synthesized in an E. coli. G-CSF induces the generation and differentiation of neutrophils out of the late progenitor cells, facilitates their phagocytic activity, mobilizes hematopoietic (CD34+) cells, part of them bearing the G-CSF receptor (CD114+). There is data evidencing a defect in the synthesis of endogenous G-CSF in patients with CHC undergoing AVT [1, 5] . There are no dosing regimens available yet in relation to Filgrastim for patients receiving AVT.
28 patients who developed neutropenia (<1×10 9 /l -1000 cells/mcl) had Filgrastim (Neupomax) administered at an initial dose of 300 μg once per week, two days before or two days after the introduction of IFN-α. Filgrastim was introduced on Week 4 through Week 12, depending on the neutropenia development terms. Further on the dosage and the mode of administration were selected on an individual basis -2 patients got the medicine at 300 μg twice a week; 10 patients -300 μg once a week; 16 -300 μg -once every two weeks. As Filgrastim was administered the level of endotoxinemia decreased significantly (p<0.05) while the patients demonstrated a better well-being status (evaluated with Beck Scale). None of those who got G-CSF had any infectious complications. Introduction of Filgrastim allowed maintaining the level of neutrophils at no lower than 1.0-1.5×10 9 /l thus preventing the need to reduce the interferon doses.
Reports on research projects like described above are far from being abundant. In a study run by J. Koirala et al. all the patients were treated with Pegasys, and Filgrastim was administered in case of neutropenia below 1000 cells/mcl, on average after 13 weeks, 300 μg once a week, after which the dosage remained the same depending on the level of neutrophils achieved [9] . When needed the dose of Filgrastim had to be taken up to 480 μg, while in case of complete response it was reduced down to 150 μg. At the same time no patient developed any neutropenia-associated infectious complications; besides, none of those belonging to the group that was given G-CSF discontinued the antiviral therapy early. The conclusion made here is that the purpose for the therapy should be a level of neutrophils at 1000 cells/mcl and not the baseline level [9] . In another study, in case of neutropenia developing <1000 cells/mcl, the maintenance of the PEG-IFN dose against Filgrastim introduced at 150-300 μg twice a week, resulted in sustained virological response (SVR) more often rather than in cases where the interferon doses were reduced: 30% vs. 21% [20] .
Filgrastim, if introduced, will bring up the cost of the therapy, so some authors still remain doubtful when it comes to justifying the need for its administration. However, the level of adherence to AVT and successful outcome is higher in patients with no haematologic disturbances (58% vs. 25%) [11] . A pharmacoeconomic analysis has shown that G-CSF taken in the dose of 300 μg once a week is economically profitable when talking of patients with HCV genotype 1 and neutropenia, yet not patients with HCV genotypes 2 and 3, especially when introduced in the first 12 weeks as this is exactly the time when forced reduction of antiviral drugs doses shall have the highest impact on the frequency of sustained virological response [3, 4] . Mention to be made here that within this particular period we observed a reduction in the number of neutrophils and an increase in neutropenia-associated endotoxinemia. Conclusion 1. Patients with chronic hepatitis C, when undergoing combined antiviral therapy, have their levels of neutrophils going down starting from Week 2 already, while the minimum counts are observed by Week 12 of the therapy. Neutropenia shall develop more often when pegylated IFNα is used.
2. Neutropenia developing against antiviral treatment offered to patients with CHC is associated with an increase in the serum levels of endotoxin. There has been an inverse relationship found between endotoxinemia and neutrophil counts in the peripheral blood.
3. Introduction of G-CSF allows stabilizing the level of neutrophils, reducing endotoxinemia, improving significantly the patients' well-being as well as their tolerance to the antiviral therapy, also preventing interferon doses reduction.
